Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-10-24 Capital/Financing Update
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
[기재정정]타법인주식및출자증권취득결정
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the decision to acquire shares and investment securities of another company, including specifics such as acquisition dates, amounts, ownership percentages, and related board resolutions. It includes financial data about the target company and the acquiring company's intentions. This type of document is an update on capital investment activities, specifically about acquiring shares in another company. It is not a full financial report, earnings release, or management discussion. It is not a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes through share acquisition.
2025-10-24 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the decision to acquire shares and investment securities in another company (GemVax & Kael). It includes specifics such as the number of shares to be acquired, acquisition amount, ownership percentages before and after acquisition, acquisition method, purpose, scheduled acquisition date, and related financial data of the target company. The document also mentions the board resolution date and attendance, and provides summarized financial information of the issuing company. The content focuses on a capital investment transaction rather than a financial report, earnings release, or regulatory certification. It is not a full annual or interim report, nor a simple announcement of a report publication. The document fits the category of Capital/Financing Update (CAP) as it details a financing activity involving share acquisition and capital investment.
2025-10-02 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a 'Correction Report' (정정신고) for a previously disclosed 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to the contract amount and percentage of revenue. Since this is a specific regulatory disclosure regarding a material contract update filed with the Korea Exchange (KRX), and it does not fit into the specific categories like financial reports or shareholder meetings, it falls under the general regulatory filing category.
2025-08-25 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of convertible bonds (CB) by '제스트 신기술조합 제76호' in '삼성제약(주)', resulting in a reportable ownership stake. This document type is specifically used for major shareholding notifications (crossing thresholds) and is classified as MRQ.
2025-08-22 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Samsung Pharmaceutical regarding the issuance results of convertible bonds (a type of capital-related security). It details the issuance method, amount, and payment date. This falls under the category of share issuance or capital changes, specifically related to the issuance of convertible securities.
2025-08-21 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It is explicitly labeled as a 'Correction Report' (정정신고), detailing changes to the issuance amount, payment dates, and conversion terms of previously announced convertible bonds. This falls under the category of capital and financing updates.
2025-08-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.